Shanxi C&Y Pharmaceutical Group Co Ltd (300254) — Working Capital to Net Assets Ratio
Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Working Capital to Net Assets ratio of -1.7% as of March 2026. Working capital of CN¥-8.77 Million (current assets of CN¥563.64 Million minus current liabilities of CN¥572.41 Million) is measured against net assets of CN¥514.07 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shanxi C&Y Pharmaceutical Group Co Ltd (300254) financial flexibility to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shanxi C&Y Pharmaceutical Group Co Ltd Working Capital to Net Assets (2008–2025)
This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the ratio stands at -1.7%, reflecting working capital of CN¥-8.77 Million against net assets of CN¥514.07 Million CNY. See 300254 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Shanxi C&Y Pharmaceutical Group Co Ltd.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -2.2% | CN¥-13.15 Million | CN¥594.33 Million | CN¥604.06 Million | CN¥617.21 Million | ▲ +9.5 pp |
| 2024 | -11.7% | CN¥-69.94 Million | CN¥598.18 Million | CN¥500.87 Million | CN¥570.81 Million | ▼ -9.7 pp |
| 2023 | -2.0% | CN¥-15.82 Million | CN¥778.43 Million | CN¥406.55 Million | CN¥422.37 Million | ▲ +10.5 pp |
| 2022 | -12.6% | CN¥-91.65 Million | CN¥729.68 Million | CN¥508.03 Million | CN¥599.68 Million | ▼ -9.3 pp |
| 2021 | -3.2% | CN¥-24.14 Million | CN¥744.58 Million | CN¥375.89 Million | CN¥400.03 Million | ▼ -13.4 pp |
| 2020 | 10.2% | CN¥89.01 Million | CN¥872.61 Million | CN¥578.91 Million | CN¥489.90 Million | ▼ -17.1 pp |
| 2019 | 27.3% | CN¥254.97 Million | CN¥932.60 Million | CN¥648.18 Million | CN¥393.21 Million | ▲ +2.0 pp |
| 2018 | 25.4% | CN¥236.31 Million | CN¥931.24 Million | CN¥634.86 Million | CN¥398.55 Million | ▲ +12.3 pp |
| 2017 | 13.0% | CN¥126.53 Million | CN¥971.17 Million | CN¥602.79 Million | CN¥476.25 Million | ▼ -8.4 pp |
| 2016 | 21.5% | CN¥205.03 Million | CN¥954.85 Million | CN¥533.97 Million | CN¥328.94 Million | ▼ -4.7 pp |
| 2015 | 26.2% | CN¥228.38 Million | CN¥872.50 Million | CN¥491.01 Million | CN¥262.63 Million | ▲ +9.4 pp |
| 2014 | 16.7% | CN¥137.75 Million | CN¥823.16 Million | CN¥370.04 Million | CN¥232.29 Million | ▲ +2.5 pp |
| 2013 | 14.3% | CN¥109.57 Million | CN¥767.16 Million | CN¥302.39 Million | CN¥192.82 Million | ▼ -36.8 pp |
| 2012 | 51.1% | CN¥332.86 Million | CN¥651.17 Million | CN¥487.13 Million | CN¥154.27 Million | ▼ -19.9 pp |
| 2011 | 71.1% | CN¥412.94 Million | CN¥581.17 Million | CN¥534.34 Million | CN¥121.39 Million | ▲ +65.9 pp |
| 2010 | 5.1% | CN¥7.68 Million | CN¥149.59 Million | CN¥138.93 Million | CN¥131.25 Million | ▼ -26.7 pp |
| 2009 | 31.9% | CN¥37.48 Million | CN¥117.60 Million | CN¥159.38 Million | CN¥121.91 Million | ▼ -11.0 pp |
| 2008 | 42.9% | CN¥45.72 Million | CN¥106.70 Million | CN¥123.17 Million | CN¥77.45 Million | — |